Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis

Maria Pia Amato, Benedetta Goretti, Vincenzo Brescia Morra, Paolo Gallo, Mauro Zaffaroni, Marco Onofrj, Eleonora Cocco, Giovanna Borriello, Valentina Zipoli, Maria Trojano

Research output: Contribution to journalArticle

Abstract

Background: A significant proportion of patients with multiple sclerosis (MS) show cognitive impairment. Objective: To evaluate the effect of 2-year treatment with oral dimethyl fumarate (DMF) on cognition in relapsing remitting MS (RRMS). Methods: In this prospective single-arm study RRMS patients treated with DMF underwent a wide battery of tests, including an extensive neuropsychological evaluation, clinical and patient-reported outcomes (PROs) and quality of life (QoL). Primary endpoints were the proportion of patients with cognitive impairment at baseline and of patients with cognitive worsening over 2 years. Results: Overall, 217 patients (74.2% females, mean age 37.3 years) receiving DMF were recruited, and 156 (67.2%) completed the study. Of the 49 patients with cognitive impairment at baseline, 34 had 2-year data: 15 (44.1%) patients worsened and 19 (55.9%) did not. The cognitive impairment index improved in one third of patients at 2 years. Less than 20% of patients had relapses at 2 years (annualized relapse rate: 0.190). Few patients had disability progression. PROs (fatigue, depression, impairment in work/social activities), QoL, and most of neuropsychological tests significantly improved vs. baseline. Conclusion: The 2-year treatment with DMF was associated with slowing of cognitive impairment and with significant improvements in QoL and psychosocial function.

Original languageEnglish
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - Jan 1 2020

Keywords

  • Cognition
  • Dimethyl fumarate
  • Relapsing remitting multiple sclerosis

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Amato, M. P., Goretti, B., Brescia Morra, V., Gallo, P., Zaffaroni, M., Onofrj, M., Cocco, E., Borriello, G., Zipoli, V., & Trojano, M. (Accepted/In press). Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences. https://doi.org/10.1007/s10072-020-04320-w